Citation Impact
Citing Papers
2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2017 Standout
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
2011 Standout
Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer
2014 StandoutNobel
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
2008 Standout
Metastasis: from dissemination to organ-specific colonization
2009 Standout
Tumour-cell invasion and migration: diversity and escape mechanisms
2003 Standout
Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study
2007
Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer
2008
The DNA-damage response in human biology and disease
2009 StandoutNature
The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin
2008
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
2007 Standout
Smarter drugs emerging in pancreatic cancer therapy
2014
Emerging insights into the molecular and cellular basis of glioblastoma
2012
EGFR Antagonists in Cancer Treatment
2008 Standout
Src activation of Stat3 is an independent requirement from NF-κB activation for constitutive IL-8 expression in human pancreatic adenocarcinoma cells
2006
Cancer Invasion and the Microenvironment: Plasticity and Reciprocity
2011 Standout
Pancreatic cancer
2004 Standout
Matrix metalloproteinases and the regulation of tissue remodelling
2007 Standout
Inflammation and cancer
2002 StandoutNature
Thrombotic and Bleeding Complications of Prosthetic Heart Valves
1987
Cancer Metastasis: Building a Framework
2006 Standout
Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy
2001
Low-Density Lipoprotein Receptor-Related Protein-1 Mediates Endocytic Clearance of Tissue Inhibitor of Metalloproteinases-1 and Promotes Its Cytokine-Like Activities
2014 StandoutNobel
Advanced pancreatic carcinoma: current treatment and future challenges
2010
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
2015 StandoutNature
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
2010 StandoutNature
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Pancreatic cancer
2016 Standout
Strategies for MMP inhibition in cancer: innovations for the post-trial era
2002
Inhibition of angiogenesis and invasion in malignant gliomas
2007
Physiological levels of tumstatin, a fragment of collagen IV α3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via αVβ3 integrin
2003
Osteoarthritis
2015 Standout
Asthma
2017 Standout
Pancreatic Adenocarcinoma
2014 Standout
Angiogenesis in life, disease and medicine
2005 StandoutNature
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
2010 Standout
Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets
2002
Inhibition of cervical lymph node metastasis by marimastat (BB-2516) in an orthotopic oral squamous cell carcinoma implantation model
2002
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
2013 Standout
Fevipiprant, a prostaglandin D 2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial
2016
Remodelling the extracellular matrix in development and disease
2014 Standout
Malignant Gliomas in Adults
2008 Standout
TIMPs as multifacial proteins
2004
Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?
2007 Standout
STATs in cancer inflammation and immunity: a leading role for STAT3
2009 Standout
Classification of anticancer drugs—a new system based on therapeutic targets
2003
Novel targets in gastric and esophageal cancer
2006
Small cell lung cancer: the importance of the extracellular matrix
2004
Role of gemcitabine in cancer therapy
2005
Pancreatic Cancer
2010 Standout
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
Prostate Stem Cell Antigen Is a Putative Target for Immunotherapy in Pancreatic Cancer
2005
Asymmetric Multicomponent Reactions (AMCRs): The New Frontier
2005 Standout
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
2009 Standout
Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy
2006
New functions for the matrix metalloproteinases in cancer progression
2002 Standout
Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies
2004
Angiogenesis as a therapeutic target
2005 StandoutNature
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
The role of matrix metalloproteinases in the pathophysiology and progression of human nervous system malignancies: a chance for the development of targeted therapeutic approaches?
2008
Pancreatic cancer
2011 Standout
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer
2005
A crucial role for Lyn in TIMP‐1 erythroid cell survival signalling pathway
2013 StandoutNobel
Iron-Catalyzed Reactions in Organic Synthesis
2004 Standout
Autocrine Motility Factor Signaling Enhances Pancreatic Cancer Metastasis
2004
Synergistic Antipancreatic Tumor Effect by Simultaneously Targeting Hypoxic Cancer Cells With HSP90 Inhibitor and Glycolysis Inhibitor
2008
Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group
2006 Standout
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
VEGF Secreted by Hypoxic Müller Cells Induces MMP-2 Expression and Activity in Endothelial Cells to Promote Retinal Neovascularization in Proliferative Diabetic Retinopathy
2013 StandoutNobel
New Strategies for Fluorescent Probe Design in Medical Diagnostic Imaging
2009 Standout
Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy
2004 Standout
Genes and pathways downstream of telomerase in melanoma metastasis
2006 StandoutNobel
Metastatic Pancreatic Cancer 2008: Is the Glass Less Empty?
2008
The Pancreas Cancer Microenvironment
2012
Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer
2007
Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer
2004
Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions
2005
Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial
2005
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2020 Standout
Irinotecan Plus Oxaliplatin and Leucovorin-Modulated Fluorouracil in Advanced Pancreatic Cancer—A Groupe Tumeurs Digestives of the Fédération Nationale des Centres de Lutte Contre le Cancer Study
2005
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
2002 StandoutScience
Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor.
2003
Clinical Benefit and Quality of Life in Patients With Advanced Pancreatic Cancer Receiving Gemcitabine Plus Capecitabine Versus Gemcitabine Alone: A Randomized Multicenter Phase III Clinical Trial—SAKK 44/00–CECOG/PAN.1.3.001
2008
Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases
2003 Standout
Metalloproteinase inhibitors: biological actions and therapeutic opportunities
2002
Design and Therapeutic Application of Matrix Metalloproteinase Inhibitors
1999
Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review)
2010
Role of Matrix Metalloproteinase-7 (Matrilysin) in Human Cancer Invasion, Apoptosis, Growth, and Angiogenesis
2006
Works of M Baillet being referenced
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer
2002
Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen
1999
Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial
2002
Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation★
2006
Plasma beta-thromboglobulin in patients with valvular heart disease with or without valve replacement: Relationship with thromboembolic accidents
1984
Heightened response of eosinophilic asthmatic patients to the CRTH 2 antagonist OC 000459
2014
Tumour marker levels during marimastat therapy
1996